-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Acurx Pharmaceuticals (NASDAQ:ACXP) Research Coverage Started at HC Wainwright
Acurx Pharmaceuticals (NASDAQ:ACXP) Research Coverage Started at HC Wainwright
HC Wainwright assumed coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a research note published on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 target price on the stock. HC Wainwright also issued estimates for Acurx Pharmaceuticals' Q4 2022 earnings at ($0.25) EPS, FY2022 earnings at ($1.07) EPS, Q1 2023 earnings at ($0.27) EPS, Q2 2023 earnings at ($0.24) EPS, Q3 2023 earnings at ($0.22) EPS, Q4 2023 earnings at ($0.27) EPS, FY2023 earnings at ($0.99) EPS, FY2024 earnings at ($1.19) EPS, FY2025 earnings at ($1.42) EPS and FY2026 earnings at ($0.95) EPS.
Separately, Alliance Global Partners assumed coverage on Acurx Pharmaceuticals in a report on Thursday, October 20th. They issued a buy rating on the stock.
Get Acurx Pharmaceuticals alerts:Acurx Pharmaceuticals Trading Up 1.3 %
Shares of NASDAQ ACXP opened at $3.85 on Monday. The firm has a market cap of $44.63 million, a P/E ratio of -3.61 and a beta of -0.73. Acurx Pharmaceuticals has a 1-year low of $2.33 and a 1-year high of $4.89. The business's 50 day moving average is $3.20 and its 200-day moving average is $3.49.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.32) EPS for the quarter.Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Castle Wealth Management LLC bought a new stake in Acurx Pharmaceuticals in the 2nd quarter valued at about $49,000. BlackRock Inc. boosted its stake in shares of Acurx Pharmaceuticals by 149.8% in the 1st quarter. BlackRock Inc. now owns 16,699 shares of the company's stock worth $55,000 after buying an additional 10,014 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Acurx Pharmaceuticals in the 3rd quarter worth approximately $3,198,000. Finally, Semmax Financial Advisors Inc. lifted its stake in Acurx Pharmaceuticals by 365.5% in the second quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock valued at $28,000 after purchasing an additional 4,616 shares during the last quarter. 3.03% of the stock is owned by institutional investors.
Acurx Pharmaceuticals Company Profile
(Get Rating)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Further Reading
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
HC Wainwright assumed coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a research note published on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 target price on the stock. HC Wainwright also issued estimates for Acurx Pharmaceuticals' Q4 2022 earnings at ($0.25) EPS, FY2022 earnings at ($1.07) EPS, Q1 2023 earnings at ($0.27) EPS, Q2 2023 earnings at ($0.24) EPS, Q3 2023 earnings at ($0.22) EPS, Q4 2023 earnings at ($0.27) EPS, FY2023 earnings at ($0.99) EPS, FY2024 earnings at ($1.19) EPS, FY2025 earnings at ($1.42) EPS and FY2026 earnings at ($0.95) EPS.
據The Fly報道,HC Wainwright在週一上午發佈的一份研究報告中假設了Acurx PharmPharmticals(納斯達克:ACXP-GET Rating)的股票。該公司對該股發佈了買入評級和14.00美元的目標價。HC Wainwright還發布了對Acurx製藥公司2022年第四季度每股收益(0.25美元)、2022財年每股收益(1.07美元)、2023年第一季度每股收益(0.27美元)、2023年第二季度每股收益(0.24美元)、2023年第三季度每股收益(0.22美元)、2023年第四季度每股收益(0.27美元)、2023財年每股收益(0.99美元)、2024財年每股收益(1.19美元)、2025財年每股收益(1.42美元)和2026財年每股收益(0.95美元)的預期。
Separately, Alliance Global Partners assumed coverage on Acurx Pharmaceuticals in a report on Thursday, October 20th. They issued a buy rating on the stock.
另外,Alliance Global Partners在10月20日星期四的一份報告中對Acurx製藥公司進行了報道。他們對這只股票發佈了買入評級。
Acurx Pharmaceuticals Trading Up 1.3 %
Acurx製藥公司股價上漲1.3%
Shares of NASDAQ ACXP opened at $3.85 on Monday. The firm has a market cap of $44.63 million, a P/E ratio of -3.61 and a beta of -0.73. Acurx Pharmaceuticals has a 1-year low of $2.33 and a 1-year high of $4.89. The business's 50 day moving average is $3.20 and its 200-day moving average is $3.49.
週一,納斯達克ACXP的股價開盤報3.85美元。該公司市值為4463萬美元,本益比為-3.61,貝塔係數為-0.73。Acurx PharmPharmticals的一年低點為2.33美元,一年高位為4.89美元。該業務的50日移動均線切入位在3.20美元,200日移動均線切入位在3.49美元。
Institutional Inflows and Outflows
機構資金流入和流出
Hedge funds have recently made changes to their positions in the business. Castle Wealth Management LLC bought a new stake in Acurx Pharmaceuticals in the 2nd quarter valued at about $49,000. BlackRock Inc. boosted its stake in shares of Acurx Pharmaceuticals by 149.8% in the 1st quarter. BlackRock Inc. now owns 16,699 shares of the company's stock worth $55,000 after buying an additional 10,014 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Acurx Pharmaceuticals in the 3rd quarter worth approximately $3,198,000. Finally, Semmax Financial Advisors Inc. lifted its stake in Acurx Pharmaceuticals by 365.5% in the second quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock valued at $28,000 after purchasing an additional 4,616 shares during the last quarter. 3.03% of the stock is owned by institutional investors.
對沖基金最近對其在該業務中的頭寸進行了調整。Castle Wealth Management LLC在第二季度購買了Acurx PharmPharmticals的新股份,價值約4.9萬美元。貝萊德股份有限公司在第一季度增持了149.8%的Acurx製藥股份。貝萊德股份有限公司在上個季度增持了10,014股後,現在持有16,699股該公司股票,價值55,000美元。停戰資本有限責任公司在第三季度購買了價值約319.8萬美元的Acurx製藥公司的新頭寸。最後,Semmax Financial Advisors Inc.在第二季度將其在Acurx PharmPharmticals的持股比例提高了365.5%。Semmax Financial Advisors Inc.現在持有該公司5,879股股票,價值28,000美元,該公司在上個季度又購買了4,616股股票。3.03%的股份由機構投資者持有。
Acurx Pharmaceuticals Company Profile
Acurx製藥公司簡介
(Get Rating)
(獲取評級)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Acurx製藥公司是一家臨床階段的生物製藥公司,開發用於治療細菌感染的抗生素。它的主要候選抗生素是ibezapolstat,這是一種新的作用機制,針對的是聚合酵素IIIC酵素,該酵素已經完成了治療艱難梭菌感染的IIa期臨床試驗。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- 免費獲取StockNews.com關於Acurx製藥的研究報告(ACXP)
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
- 機構將Rite Aid的股票跌至谷底
- 這就是為什麼你應該避開聯盟快遞的反彈
- 維京治療公司股票為何暴漲
- 耐克公司業績和前景走高
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Acurx製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acurx製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧